Y-mAbs Therapeutics Inc. reported its financial results for the first quarter of 2025. The company reported net product revenues of $20.9 million, marking an approximately 8% increase from the previous year. The net loss for the quarter ended March 31, 2025, was $5.2 million, compared to a net loss of $6.6 million for the same period in 2024. This decrease in net loss was primarily driven by increased total revenues and foreign currency transactional gains, despite increased operating costs and expenses. The company also reported an increase in interest and other income to $1.4 million, up from $0.4 million in the prior year, primarily due to a $1.3 million increase in foreign currency transaction gains. As of March 31, 2025, Y-mAbs had approximately $60.3 million in cash and cash equivalents, which, along with anticipated revenues from its product DANYELZA, is expected to support operations into 2027. In terms of business developments, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroblastoma have been updated to include naxitamab-gqgk (DANYELZA). Additionally, the company dosed its first patient in a Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with relapsed/refractory non-Hodgkin Lymphoma (Trial 1201). Y-mAbs plans to provide a virtual update on its radiopharmaceutical R&D strategy, discussing clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) on May 28, 2025. For the second quarter of 2025, Y-mAbs anticipates total revenues to be between $17 million and $19 million.